CTMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CytomX Therapeutics Inc (CTMX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment capacity. The stock shows strong upward momentum, positive analyst sentiment, and significant hedge fund interest, despite weak financial performance in the latest quarter. The recent public offering has improved liquidity, and the company's pipeline assets have significant growth potential.
The technical indicators suggest a bullish trend. The MACD histogram is positive and expanding (0.0633), the RSI_6 is at 75.181 (neutral zone), and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock has broken through key resistance levels, with the next resistance at 5.132.
Positive Phase 1 data for Varseta-M in late-line metastatic colorectal cancer, showing high efficacy and disease control rates.
Multiple analysts have raised price targets significantly, with targets ranging from $11 to $
Hedge funds are aggressively buying, with a 1979% increase in buying activity over the last quarter.
The company completed a $250 million public offering to enhance liquidity and fund projects.
Insiders are selling, with a 457.87% increase in selling activity over the last month.
Weak financial performance in Q4 2025, with revenue down 98.26% YoY, net income down 256.35% YoY, and EPS down 177.27% YoY.
The company's Q4 2025 financials were weak, with revenue dropping to $663,000 (-98.26% YoY), net income dropping to -$29.51 million (-256.35% YoY), and EPS falling to -0.17 (-177.27% YoY). However, gross margin remained stable at 100%.
Analysts are overwhelmingly positive on CTMX, with multiple firms raising price targets significantly (e.g., Barclays to $16, Jefferies to $16, Guggenheim to $15, and H.C. Wainwright to $17). Analysts highlight the potential of Varseta-M as a game-changer in colorectal cancer treatment, with peak sales estimates of $1.5B in late-line CRC and further upside potential.
